Clinical trials: Weakness
Type2 Diabetes, Diabetic Retinopathy
Tangningtongluo Tablet in the Treatment of Non-proliferative Diabetic Retinopathy
This trial is planned to collect relevant clinical data to evaluate the prevention efficacy and safety of Tangningtongluo tablets on the non-proliferation period of diabetic retinopathy.
- Trial name
- NCT05007262
- Testing
- Tangningtongluo tablets, Calcium dobesilate capsules
- Where
- 13 sites in China
- Volunteers
- 240 people
- Sponsor
- Guizhou Bailing Group Pharmaceutical Co Ltd
Thymidine Kinase 2 Deficiency
A Study of the Efficacy and Safety of MT1621 in Thymidine Kinase 2 (TK2) Deficiency (Treatment naïve)
This is a Phase 3b, prospective, single-arm, multicenter, open-label treatment study of the efficacy and safety of MT1621 in pediatric and adolescent patients with thymidine kinase 2 deficiency (TK2d).
- Trial name
- NCT04581733
- Testing
- MT1621
- Sponsor
- Zogenix MDS, Inc.
CVA (Cerebrovascular Accident)
Wearable Robotic Functional Assistance for Stroke Rehabilitation
This study aims to evaluate the effectiveness of using the myomo e100 wearable robotic rehabilitation system for increasing functional independence and long term rehabilitation of chronic stroke victims with a hemiparetic upper…
- Trial name
- NCT00396708
- Testing
- myomo e100 neurorobotic elbow brace
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Myomo
Fecal Incontinence
Evaluation of Outcomes of Restoring Pelvic Floor Support With TOPAS in Women With Moderate Fecal Incontinence Symptoms
The study purpose is to gain experience with the TOPAS system, a minimally- invasively delivered self-fixating mesh for the treatment of pelvic floor weakness in women with symptoms of moderate fecal incontinence
- Trial name
- TOPAS (NCT00565136)
- Testing
- TOPAS
- Where
- 5 sites in United States
- Volunteers
- 29 people
- Sponsor
- ASTORA Women's Health
Immobility and Weakness Associated With Long Intensive Care Unit Stays
Early Progressive Mobility in the CVICU: Assessing Current Status
The current study is proposed to assess the frequency and type of progressive mobility procedures currently performed in the CVICU The study will evaluate the type and frequency of progressive mobility orders, whether or not…
- Trial name
- NCT01295541
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Hill-Rom
Myasthenia Gravis
A Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of ARGX-113 in Patients With Myasthenia Gravis Who Have Generalized Muscle Weakness
This is a randomized, double-blind, placebo-controlled, multicenter Phase II study to evaluate the safety, efficacy, and pharmacokinetics of ARGX-113 for the treatment of autoimmune Myasthenia Gravis (MG) with generalized muscle…
- Trial name
- NCT02965573
- Testing
- ARGX-113
- Where
- 19 sites in United States, Belgium and 6 more
- Volunteers
- 24 people
- Sponsor
- argenx
Pelvic Floor Disorders, Pelvic Pain
Digital Care Programs for Female Pelvic Health
The purpose of this study is to create a research repository, composed of data collected in the course of digital care programs for pelvic health conditions by SWORD Health/Bloom to individuals undergoing those programs.
- Conditions
- Pelvic Floor Disorders, Pelvic Pain, Pelvic Organ Prolapse, Pelvic Floor Muscle Weakness
- Trial name
- NCT05513417
- Testing
- Bloom Pod
- Where
- United States
- Volunteers
- 50,000 people, healthy volunteers welcome
- Sponsor
- Sword Health, SA
Healthy
Evaluate the Effect of Ethinyl Estradiol/Norgestimate on the Pharmacokinetics of Lomitapide in Healthy Female Subjects
The primary objective of this study is to assess the effect of ethinyl estradiol (EE)/norgestimate, a weak cytochrome P450 (CYP) 3A4 inhibitor, on the pharmacokinetics (PK) of lomitapide and 2 primary metabolites, M1 and M3.
- Trial name
- NCT02080468
- Testing
- lomitapide, EE/norgestimate
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Aegerion Pharmaceuticals, Inc.
Stroke, Acute, Stroke, Ischemic
Effects of Atalante Exoskeleton on Gait Recovery in Non- or Poorly Ambulatory Patients With Hemiparesis in the Acute/Subacute Phase (Month 1 to 4)
The present clinical investigation - EarlyExo, is an interventional, international, multicentric, prospective, single-blinded randomized controlled trial.
- Conditions
- Stroke, Acute, Stroke, Ischemic, Stroke, Subacute, Stroke Hemorrhagic
- Trial name
- EarlyExo (NCT06107010)
- Testing
- Use of the Atalante exoskeleton
- Where
- 5 sites in France, Germany and 1 more
- Volunteers
- 66 people
- Sponsor
- Wandercraft
Muscle Strength, Muscle Weakness
Performance Output With Haptics - Evaluating Athlete Response and Unrealized Potential
This minimal risk, randomized, double-blind, placebo controlled Institutional Review Board (IRB)-approved observational study with functional measurements, will evaluate athletic performance after use of a drug- free…
- Trial name
- POWER-UP (NCT06430879)
- Testing
- VICTORY PATCH
- Where
- United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- SuperPatch Limited LLC
Post-acute COVID-19 Syndrome
Сlinical Trial of Efficacy and Safety of Prospekta in the Treatment of Post-COVID-19 Asthenia.
The multicenter, double-blind, placebo-controlled, parallel-group, randomized clinical trial. The objective of this study is to evaluate the efficacy and safety of Prospekta in the treatment of asthenia in patients after the…
- Trial name
- NCT05074888
- Testing
- Prospekta
- Where
- 32 sites in Russia
- Volunteers
- 676 people
- Sponsor
- Materia Medica Holding
Generalized Myasthenia Gravis
A Safety and Tolerability Study of ARGX-113 in Patients With Myasthenia Gravis Who Have Generalized Muscle Weakness.
This is a Long-Term, Single-Arm, Open-Label, Multicenter Phase 3 follow-on trial of the ARGX-113-1704 study to evaluate the safety and tolerability of ARGX-113 in patients with gMG.
- Trial name
- ADAPT+ (NCT03770403)
- Testing
- ARGX-113
- Where
- 52 sites in United States, Belgium and 13 more
- Volunteers
- 151 people
- Sponsor
- argenx
Mitochondrial Myopathies, Mitochondrial Pathology
Study to Evaluate Efficacy and Safety of Elamipretide in Subjects With Primary Mitochondrial Disease From Nuclear DNA Mutations (nPMD)
SPIMD-301 is a 48-week, randomized, double-blind, parallel-group, placebo-controlled trial to assess efficacy and safety of single daily subcutaneous (SC) administration of elamipretide as a treatment for subjects with primary…
- Conditions
- Mitochondrial Myopathies, Mitochondrial Pathology, Mitochondrial DNA Mutation, Mitochondrial Diseases
- Trial name
- NuPower (NCT05162768)
- Testing
- Elamipretide
- Where
- 32 sites in United States, Australia and 8 more
- Volunteers
- 102 people
- Sponsor
- Stealth BioTherapeutics Inc.
Peripheral Neuropathy, Muscle Weakness
Biomarker for Metachromatic Leukodystrophy (BioMeta) Disease
Development of a new MS-based biomarker for the early and sensitive diagnosis of Metachromatic Leu-kodystrophy disease from blood (plasma)
- Trial name
- BioMeta (NCT01536327)
- Where
- 5 sites in Egypt, Germany and 2 more
- Sponsor
- CENTOGENE GmbH Rostock
Muscle Weakness
Functional Change With MMS
Evaluate the safety and efficacy of magnetic muscle stimulation (MMS) of abdominal muscle.
- Trial name
- FMS (NCT04506502)
- Testing
- The ZELTIQ System
- Where
- United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Zeltiq Aesthetics
Debility Due to Disease
Exoskeleton Treatment of Deconditioning Due to Limited Ambulation Caused by Illness or Injury
A safety and feasibility study of robotic exoskeleton training in deconditioned patients residing in a healthcare facility.
- Trial name
- NCT03355755
- Testing
- EksoGT with SmartAssist software
- Where
- 3 sites in United States
- Volunteers
- 15 people
- Sponsor
- Ekso Bionics
Muscle Weakness
Combination Treatment With BTL-899 and HPM-6000UF Devices II
This study will evaluate the clinical efficacy of the BTL-899 and HPM-6000UF devices in combination for non-invasive strengthening of the core muscles and overall improvement in quality of life in female patients after childbirth.
- Trial name
- NCT05713864
- Testing
- BTL-899, HPM-6000UF
- Where
- 3 sites in United States
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- BTL Industries Ltd.
PreDiabetes, Older Adult
Examining the Effects of Vivo on Physical Function and Glycemic Level in Sedentary Older With Prediabetes.
This is a 12-week randomized, controlled trial that seeks to examine the effect of Vivo on 1) change in lower extremity strength defined as number of chair stands done in 30 seconds and 2) change in average glycemic level (HbA1c)…
- Conditions
- PreDiabetes, Older Adult, Muscle Loss, Muscle Weakness
- Trial name
- NCT06458530
- Testing
- Vivo
- Where
- United States
- Volunteers
- 74 people, healthy volunteers welcome
- Sponsor
- Impactiv, Inc.
Muscle Wasting, Obesity & Overweight
Testing the Efficacy, Safety, and PK of 20E in Patients With Obesity Who Are Starting Treatment With the GLP-1 Agonist Semaglutide for Weight Loss.
The goal of this clinical trial is to learn if BIO101 treatment can improve the muscle strength of participants males and females, aged 18 to 84 years old, suffering from obesity (BMI≥30) or overweight (BMI ≥ 27) with one or more…
- Conditions
- Muscle Wasting, Obesity & Overweight, Obesity
- Trial name
- OBA (NCT07411378)
- Testing
- BIO101, Semaglutide
- Volunteers
- 164 people
- Sponsor
- Biophytis
Foot Drop, Thigh Muscles Weakness (Hamstrings or Quadriceps)
Evaluation of the Safety and Performance of the NESS L300 Plus System
The study is designed to evaluate the safety and efficacy of using the L300 Plus as a neuroprosthesis device for walking in patients following an UMN injury or disease.
- Conditions
- Foot Drop, Thigh Muscles Weakness (Hamstrings or Quadriceps), Upper Motor Neuron Injury or Disease
- Trial name
- L300Plus (NCT01237860)
- Testing
- NESS L300 Plus System
- Where
- Israel
- Volunteers
- 45 people
- Sponsor
- Bioness Inc